Notice Number: NOT-OD-15-061
Release Date: January 29, 2015
Department of Health and Human Services (DHHS)
Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:
Dong Xiao, Ph.D., University of Pittsburgh: Based on the report of an inquiry conducted by the University of Pittsburgh (UP), additional analysis conducted by ORI in its oversight review, and an admission by the Respondent that he had ``intentionally fabricated data contained in a paper entitled 'Guggulsterone inhibits prostate cancer growth via inactivation of Akt regulated by ATP citrate signaling,' specifically Figure 6G,' ORI found that Dr. Dong Xiao, former Research Assistant Professor, Department of Urology, UP, engaged in research misconduct in research supported by National Cancer Institute (NCI), National Institutes of Health (NIH), grant R01 CA157477.
ORI found that Respondent engaged in research misconduct by reporting falsified data in Figures 1, 4, 5, S2, and S3 in the following paper published online:
Gao, Y., Zeng, Y., Tian, J., Kslam, M.S., Jiang, G., & Xiao, D., “Gugglesterone inhibits prostate cancer growth via inactivation of Akt regulated by ATP citrate signaling.” Oncotarget, June 26, 2014 [Epub ahead of print], PMID: 24980815; hereafter referred to as the ``Oncotarget paper.'
Specifically, in the Oncotarget paper, Respondent:
The original data showed no significant effect of either treatment in PC3 cells and no effect of Z-Gug on LNCaP cells, while both treatments were claimed to be significant inducers of caspase activity in both cell lines in the published figures.
Dr. Xiao has entered into a Voluntary Settlement Agreement (Agreement) and has voluntarily agreed for a period of three (3) years, beginning on December 23, 2014:
(1) To have his research supervised; Respondent agreed to ensure that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which the Respondent's participation is proposed and prior to Respondent's participation in any capacity on PHS-supported research, the institution employing him must submit a plan for supervision of his duties to ORI for approval; the plan for supervision must be designed to ensure the scientific integrity of Respondent's research contribution; Respondent agreed that he will not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon plan for supervision;
(2) that any institution employing him must submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and
(3) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.
Please direct all inquiries to:
Donald Wright, M.D., M.P.H.
Office of Research Integrity
1101 Wootton Parkway, Suite 750
Rockville, MD 20852